ADPT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
83.9M
+17.3%
71.6M
+1.0%
70.9M
-1.1%
71.7M
-23.7%
94.0M
Cost of Revenue
20.4M
+1.0%
20.2M
+7.8%
18.7M
+2.7%
18.2M
-1.9%
18.6M
Gross Profit
63.5M
+23.6%
51.4M
-1.5%
52.2M
-2.4%
53.5M
-29.1%
75.4M
Operating Expenses
64.0M
-4.7%
67.2M
-5.9%
71.4M
+7.8%
66.2M
+1.7%
65.1M
R&D
18.6M
-2.7%
19.2M
-18.9%
23.6M
+8.5%
21.8M
-8.1%
23.7M
SG&A
45.4M
-4.7%
47.6M
+0.5%
47.3M
+7.5%
44.0M
+6.3%
41.4M
Operating Income
-457000
+97.1%
-15770000
+17.9%
-19206000
-50.4%
-12773000
-224.1%
10.3M
EBITDA
3.1M
+126.1%
-12075000
+21.4%
-15369000
-79.2%
-8578000
-158.4%
14.7M
Net Income
2.8M
+107.0%
-39941000
-99.6%
-20015000
-47.4%
-13579000
-242.3%
9.5M
EPS (Basic)
$0.02
+108.0%
$-0.25
-92.3%
$-0.13
-44.4%
$-0.09
-250.0%
$0.06
EPS (Diluted)
$0.02
+108.0%
$-0.25
-92.3%
$-0.13
-30.0%
$-0.10
-266.7%
$0.06
Shares (Diluted)
186.9M
+16.9%
159.9M
+2.8%
155.5M
+9.2%
142.4M
-12.7%
163.2M
Adaptive Biotechnologies (ADPT) — Financials